KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to -$7.2 million.

  • Halozyme Therapeutics' Change in Accured Expenses rose 69.10% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year increase of 277.94%. This contributed to the annual value of $47.0 million for FY2024, which is 474.57% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Change in Accured Expenses stood at -$7.2 million for Q3 2025, which was up 75.87% from -$29.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Change in Accured Expenses high stood at $50.2 million for Q4 2024, and its period low was -$29.7 million during Q2 2025.
  • In the last 3 years, Halozyme Therapeutics' Change in Accured Expenses had a median value of -$2.0 million in 2023 and averaged $619,000.
  • In the last 5 years, Halozyme Therapeutics' Change in Accured Expenses crashed by 3,007.67% in 2023 and then soared by 629.44% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Change in Accured Expenses stood at $3.5 million in 2021, then slumped by 90.61% to $326,000 in 2022, then plummeted by 3,007.67% to -$9.5 million in 2023, then spiked by 629.44% to $50.2 million in 2024, then surged by 69.10% to -$7.2 million in 2025.
  • Its Change in Accured Expenses was -$7.2 million in Q3 2025, compared to -$29.7 million in Q2 2025 and $9.2 million in Q1 2025.